Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: May 12, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: KROS
TL;DR
Keros filed an 8-K, standard procedure, no major news.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this date.
Why It Matters
This filing indicates Keros Therapeutics is meeting its regulatory reporting obligations, but it does not disclose new material information that would immediately impact its stock price.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for May 12, 2025, and does not contain any new material information or events that would inherently increase risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to include Financial Statements and Exhibits as of May 12, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Keros Therapeutics, Inc.?
The Commission File Number for Keros Therapeutics, Inc. is 001-39264.
What is the business address of Keros Therapeutics, Inc.?
The business address of Keros Therapeutics, Inc. is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding Keros Therapeutics, Inc. (KROS).